Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

Garcia-Manero, G; Goldberg, AD; Winer, ES; Altman, JK; Fathi, AT; Odenike, O; Roboz, GJ; Sweet, K; Miller, C; Wennborg, A; Hickman, DK; Kanagal-Shamanna, R; Kantarjian, H; Lancet, J; Komrokji, R; Attar, EC; Sallman, DA

Sallman, DA (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA.

LANCET HAEMATOLOGY, 2023; 10 (4): E272

Abstract

Background TP53-mutated acute myeloid leukaemia is associated with poor outcomes. Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 react......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索